Other languages Neuren Pharmaceuticals Limited

Equities

Market Closed - Australian S.E. Other stock markets 02:10:06 2024-06-26 EDT			5-day change	1st Jan Change
20.86 ^AUD	+3.17%		+4.40%	-16.46%

05-28	Transcript : Neuren Pharmaceuticals Limited - Shareholder/Analyst Call
05-27	Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome	CI

Neuren Phase 2 Trial Shows Significant Improvements in Pitt Hopkins Syndrome	05-27
Neuren Pharmaceuticals Partner Acadia Pharmaceuticals Posts US DAYBUE Sales of $75.9 Million	05-09
Neuren Pharmaceuticals Posts AU$243 Million Cash, Short-Term Investments	04-23
Neuren Pharmaceuticals Limited Provides Sales Guidance for the First Quarter and Full Year 2024	02-29
Neuren Pharmaceuticals Limited Reports Earnings Results for the Full Year Ended December 31, 2023	02-28
Culper Research discloses short position in Acadia Pharma	02-15
Neuren Pharmaceuticals Completes Recruitment for Phase Two Neurological Trial; Shares Fall 4%	12-19
LATE BRIEFING - Unternehmen und Märkte	12-18
MIDDAY BRIEFING - Unternehmen und Märkte	12-18
MÄRKTE ASIEN/Gewinnmitnahmen geben Richtung vor	12-18
MÄRKTE ASIEN/Zurückhaltung vor Fed-Entscheid - Tankan-Bericht stützt Tokio	12-13
Neuren Pharmaceuticals Concludes Enrollment for Phase 2 Trial in Pitt Hopkins Syndrome	12-04
Argenica Therapeutics Appoints Nonexecutive Chair	11-29
Neuren Pharmaceuticals Limited Reiterates Net Sales Guidance for the Third Quarter of 2023	23-08-27
Neuren Pharmaceuticals Limited Reports Earnings Results for the Half Year Ended June 30, 2023	23-08-27
Sector Update: Health Care Stocks Gain Pre-Bell Friday	23-07-14
Sector Update: Health Care	23-07-14
Top Premarket Gainers	23-07-14
ACADIA Pharma Acquires Ex-North America Rights to Trofinetide, Global Rights to NNZ-2591; Shares Surge Premarket	23-07-14
Weaker-than-Expected US Data Spur Rally in Australian Shares	23-07-14

No results for this search